“The Value and Sustainability of Ocrelizumab in Relapsing Multiple Sclerosis: A Cost-Effectiveness and Budget Impact Analysis” (2019) Farmeconomia. Health economics and therapeutic pathways, 20(1). doi:10.7175/fe.v20i1.1435.